NCT04956640 2025-09-25Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Eli Lilly and CompanyPhase 1/2 Recruiting540 enrolled
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT04234113 2025-01-08Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsSotio Biotech Inc.Phase 1 Terminated115 enrolled
NCT04660929 2024-12-18CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsCarisma Therapeutics IncPhase 1 Active not recruiting48 enrolled
NCT02443324 2024-07-31A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerEli Lilly and CompanyPhase 1 Completed175 enrolled 23 charts
NCT04460456 2022-06-30A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid TumorsSilverback TherapeuticsPhase 1 Unknown58 enrolled